T wenty years after completion of the National Institute of Neurological Disorders and Stroke recombinant tissuetype plasminogen activator (r-tPA) stroke trial, 1 intravenous r-tPA remains the only proven therapy for acute ischemic stroke (AIS). The recently completed 126-patient phase II Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial found that the addition of eptifibatide, a platelet glycoprotein 2b/3a inhibitor that prevents platelet aggregation, to intravenous r-tPA had a safety profile and direction of effect in favor of the combination therapy over intravenous r-tPA.
T wenty years after completion of the National Institute of Neurological Disorders and Stroke recombinant tissuetype plasminogen activator (r-tPA) stroke trial, 1 intravenous r-tPA remains the only proven therapy for acute ischemic stroke (AIS). The recently completed 126-patient phase II Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial found that the addition of eptifibatide, a platelet glycoprotein 2b/3a inhibitor that prevents platelet aggregation, to intravenous r-tPA had a safety profile and direction of effect in favor of the combination therapy over intravenous r-tPA. 2 Although this direction of effect persisted after statistical adjustment, there were baseline imbalances in the trial in favor of the combination arm with regard to age and baseline National Institutes of Health Stroke Scale (NIHSS) Score. In this article, we compared combination therapy patients from CLEAR-ER to contemporaneously enrolled intravenous r-tPA arm patients in the phase III Interventional Management of Stroke (IMS) III 3 and the Albumin in Acute Stroke (ALIAS) Part 2 4 trials. We compared outcome using
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4 approaches variably proposed as optimal for acute stroke clinical trials.
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Methods
This was a post hoc propensity-matched analysis of data from 3 previously published randomized clinical trials. The CLEAR-ER trial was a multicenter, double-blind, randomized safety study. AIS patients treated with intravenous r-tPA within 3 hours of symptom onset were randomized to 0.6 mg/kg r-tPA plus eptifibatide (135 mcg/kg bolus and a 2-hour infusion at 0.75 mcg/kg per minute; combination arm, n=101) versus standard r-tPA (0.9 mg/kg; n=25). 10 The IMS III trial was a multicenter multinational randomized clinical trial of intravenous r-tPA plus endovascular therapy (n=434) versus intravenous r-tPA (n=222) in AIS patients treated with standard dose intravenous r-tPA within 3 hours of symptom onset. 3 The ALIAS Part 2 trial was a multicenter multinational randomized clinical trial of albumin (n=422) versus saline (n=419). 4 ALIAS Part 2 patients who were eligible for r-tPA were treated with r-tPA per standard of care.
For this analysis, we matched 2 controls among IMS III and ALIAS r-tPA only subjects for each CLEAR-ER combination arm subject using a propensity score matching approach. 11, 12 Age, sex, race, baseline modified Rankin score (mRS), baseline NIHSS score, and time from stroke onset to r-tPA initiation were included in the multivariable logistic model used to generate a propensity score for each subject. The 1:2 matching mechanism was based on a greedy algorithm, with the best match determined by the weighted sum of the absolute difference in propensity score and age between potentially matching individuals, allowing a maximum difference of 0.025 in the propensity score and 6 years for age, with the weight for the propensity score set to be double that for age. 13 Both CLEAR-ER and IMS III allowed enrollment of patients with baseline mRS >1, whereas ALIAS Part 2 only allowed patients with baseline mRS of 0 or 1. All data sets were restricted to subjects with baseline mRS of 0 or 1. Of the 101 subjects in the combination arm of CLEAR-ER, 16 were excluded for baseline mRS >1, leaving 85 subjects available for propensity matching. Of the 222 intravenous r-tPA IMS III subjects, 9 subjects were excluded (1 with baseline NIHSS missing, 4 with baseline mRS >1, and 4 with missing 90-day mRS), leaving 213 subjects available for propensity matching. Of the 419 saline patients in ALIAS Part 2, 361 received intravenous r-tPA and 16 were excluded for missing 90-day mRS, leaving 345 available for propensity matching.
The primary outcome was defined as 90-day severity-adjusted mRS dichotomization based on baseline NIHSS (favorable outcome if mRS, 0 with NIHSS, ≤7; mRS, 0 or 1 with NIHSS, 8-14; and mRS, 0-2 with NIHSS, >14). 6 Secondary outcomes included 90-day mRS dichotomization as excellent (mRS, 0-1); mRS dichotomization as favorable (mRS, 0-2); an analysis of the ordinal mRS; and NIHSS of 0 or 1 at 24 hours.
Relative risks (RR) were determined for the dichotomized efficacy outcome variables. Adjusted models included age, baseline NIHSS, and time to intravenous r-tPA using Zou modified Poisson approach. 14 The nonparametric analysis of the ordinal mRS was performed using the Van Eltren form of the Cochran-Mantel-Haenszel test using the full range of the mRS as a 6-category polychotomous outcome (collapsing mRS scores of 5 with 6). 15 Differences in proportions of favorable outcomes were also calculated with 95% confidence intervals (CI).
Results
Eighty-five combination arm CLEAR-ER subjects were matched with 169 ALIAS Part 2 and IMS III r-tPA only patients (62 IMS III and 107 ALIAS 
10).
At 24 hours, 20% of CLEAR-ER subjects had NIHSS 0 or 1 versus 14% of controls; difference in proportions 6% (−4%, 16%; P=0. 19) . Table 2 shows the adjusted and unadjusted RR and outcomes at 90 days. Table 3 shows the differences in proportions of 90-day outcomes with 95% CI. Symptomatic 
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intracranial hemorrhage rates within 36 hours were 0 (0%; 95% CI, 0-4%) in CLEAR-ER subjects and 5 (3%; 95% CI, 1-7%) in r-tPA subjects. The mRS distributions for the Cochran-Mantel-Haenszel test are shown in the Figure. On the basis of observed data for the sliding dichotomy outcome measure, the study sample size of 85 in the treatment group and 169 in the control group would achieve 80% power to detect a difference between group proportions of patients with favorable outcome of 0.18, assuming the proportion in the control group is 0.36, using a 2-sized Z test with pooled variance at a 0.05 significance level. Furthermore, if we assume the observed group difference in proportion of patients with favorable outcome of 0.09 (45% treatment and 36% control) is the minimum value worth detecting in future studies, a sample size of 466 in each group would achieve 80% power to detect this difference using a 2-sized Z test with pooled variance at a 0.05 significance level.
Discussion
In this post hoc analysis, we found a direction of effect in favor of the combination of r-tPA plus eptifibatide over r-tPA alone in AIS. These findings support a phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes.
Although sliding dichotomous or ordinal approaches have been preferentially recommended for evaluating mRS outcomes in stroke trials, [5] [6] [7] [8] [9] 16, 17 we found that of the 4 approaches analyzed, dichotomization at excellent outcomes (mRS, 0-1) demonstrated the only statistically significant finding in favor of r-tPA plus eptifibatide when compared with r-tPA. A possible explanation is that for interventions within the early time window studied, dichotomizing at mRS 0 to 1 may represent a reasonable transition point between favorable and nonfavorable outcomes. 5 Both positive trials of r-tPA in AIS showed benefit with mRS dichotomized at 0 to 1. 1, 18 However, given that the ECASS II trial showed no treatment effect with dichotomization at mRS 0 to 1 but was positive with mRS 0 to 2, 19 caution must be taken in interpreting our results and full consideration given to all approaches in selecting an analysis plan for the primary outcome in a planned phase III trial.
Compared with dichotomized favorable outcomes (mRS, 0-2), our selected primary outcome, the severity-adjusted dichotomy approach (also referred to as sliding dichotomy or responder analysis) showed a slightly stronger trend in favor of the r-tPA plus eptifibatide group over r-tPA only. The ordinal analysis showed a similar trend as the sliding dichotomy in favor of the r-tPA plus eptifibatide group compared with r-tPA. As such, despite the seemingly stronger signal of efficacy shown by dichotomization at mRS 0 or 1 in this analysis, we favor the sliding dichotomy or ordinal approach for a future trial because there is no reliable way to predict the distribution of patients who would be enrolled in such a trial. Thus, if patients with more severe strokes are enrolled, dichotomizing at mRS 1 may fail to show a treatment effect as was observed in ECASS II. 19 In addition to the inherent limitations of an unplanned post hoc analysis, limitations of this report include the small number of available r-tPA plus eptifibatide patients for analysis. Vascular imaging was not required for CLEAR-ER and the effect of combining eptifibatide with r-tPA on the insufficient arterial recanalization rates observed with r-tPA alone [20] [21] [22] remains unknown. However, the favorable direction of effect observed with r-tPA plus eptifibatide remained with comparison groups similar in age and baseline NIHSS (Table 1) and a direction of effect in favor of early improvement with the combination group based on 24-hour NIHSS of 0 or 1.
We also performed analyses using the entire data set from both ALIAS Part 2and IMS III trials, (ie, including patients who received albumin or endovascular therapy) and the results were similar with point estimates more favorable than the results presented in this article (data not shown). Exclusion of the 18 ALIAS Part 2 patients (leaving 151 r-tPA controls) also did not change our point estimates meaningfully (data not shown).
We conclude that r-tPA plus eptifibatide showed a direction of effect that was consistent across multiple approaches for outcome evaluation in AIS. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted. 
